Andere Sprachen Journey Medical Corporation

Aktien

A3C7KG

US48115J1097

DERM

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 01.05.2024			% 5 Tage	% 1. Jan.
3,51 ^USD	-4,88 %		+3,24 %	-39,06 %

21.03.	Transcript : Journey Medical Corporation, 2023 Earnings Call, Mar 21, 2024
21.03.	Journey Medical Corporation meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer	01.05.
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024	25.04.
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	21.03.
Journey Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	21.03.
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea	18.03.
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea	18.03.
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024	15.03.
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference	13.03.
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting	11.03.
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 on Microbial Flora of Healthy Adults At 2024 Annual Meeting	11.03.
Journey Medical Submits New Drug Application to FDA for Rosacea Treatment; Shares Rise	05.01.
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea	05.01.
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea	05.01.
Journey Medical Signs Credit Facility of up to $20 Million	02.01.
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million	02.01.
Journey Medical Corporation Secures Credit Facility with SWK Holdings for Up to $20 Million	02.01.
Journey Medical Corporation Announces Resignation of Jeffrey Paley as Member of the Board of Directors	08.12.
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea	06.12.
Journey Medical Corporation Announces Successful Completion of Pre-Nda Meeting with the Fda for Dfd-29 to Treat Rosacea	06.12.
Journey Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Journey Medical Corporation

Aktien

A3C7KG

US48115J1097

DERM

Andere Sprachen

Filter